News

Cyclacel Pharmaceuticals to present at Lazard Capital Markets Life Sciences Conference Short Hills, NJ, November 17, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its

Cyclacel Pharmaceuticals reports third quarter 2006 financial results Short Hills, NJ, November 13, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) today reported financial and operating results for the third quarter 2006. The company had a net loss in the quarter of $5.4

Cyclacel reports Phase I sapacitabine study results at 18th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics meeting SHORT HILLS, NJ, November 10, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today preliminary results from a Phase I clinical trial of sapacitabine (CYC682),

Cyclacel Pharmaceuticals to announce third quarter 2006 financial results on November 13, 2006 SHORT HILLS, NJ, November 6, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) will announce third quarter 2006 financial results on Monday, November 13, 2006.

Cyclacel Pharmaceuticals to present at Rodman & Renshaw annual healthcare conference SHORT HILLS, NJ, OCTOBER 30, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that two members of its executive team will present an overview of the company and its pipeline at upcoming industry

Cyclacel Pharmaceuticals names John Womelsdorf, Ph.D., Vice President, Business Development SHORT HILLS, NJ, October 24, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that John Womelsdorf, Ph.D., has joined the company as Vice President, Business Development. Dr.

Cyclacel Pharmaceuticals to present at C.E. Unterberg, Towbin Emerging Opportunities in Healthcare Conference SHORT HILLS, NJ, OCTOBER 24, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the

Cyclacel Pharmaceuticals, Inc. announces quarterly dividend for 6% Convertible Exchangeable Preferred Stock SHORT HILLS, NJ, October 23, 2006 - Cyclacel Pharmaceuticals, Inc. ("Cyclacel", the "Company") (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that the Company's Board of Directors has

Cyclacel Pharmaceuticals to present at Thomson Financial and Biocentury's: NewsMakers in the Biotech Industry Conference SHORT HILLS, NJ, SEPTEMBER 5, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an

Cyclacel Pharmaceuticals Reports Second Quarter 2006 Financial Results Short Hills, NJ, August 14, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) today reported financial and operating results for the second quarter 2006. The Company had a net loss in the quarter of $6.9

Cyclacel Pharmaceuticals, Inc. Announces Quarterly Dividend For 6% Convertible Exchangeable Preferred Stock SHORT HILLS, NJ, July 19, 2006 – Cyclacel Pharmaceuticals, Inc. ("Cyclacel", the "Company") (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that the Company's Board of Directors has declared a

Cyclacel Begins A Phase IIb Randomized Trial Of Seliciclib For Previously Treated Non-Small Cell Lung Cancer SHORT HILLS, NJ, June 29, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that the company is beginning a Phase IIb, multi-center, randomized, double-blinded trial to

Cyclacel Begins Phase I Pharmacologic Study Of Oral Sapacitabine In Patients With Advanced Leukemias SHORT HILLS, NJ, JUNE 15, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that the company has initiated a Phase I clinical trial of sapacitabine (CYC682), an orally available

Cyclacel Pharmaceuticals To Present At 5th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference 2006 SHORT HILLS, NJ, JUNE 12, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an

Cyclacel Pharmaceuticals To Present At Bioequity Europe 2006 SHORT HILLS, NJ, MAY 18, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Paul McBarron, Executive Vice President, Finance and Chief Operating Officer, will present an overview of the Company and its pipeline at

Cyclacel Pharmaceuticals To Present At Rodman And Renshaw 3rd Annual Global Healthcare Conference SHORT HILLS, NJ, MAY 4, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its

Cyclacel Pharmaceuticals Announces $45 Million Private Placement SHORT HILLS, NJ, April 27, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that the Company has entered into a definitive agreement to raise approximately $45.3 million in a private placement of approximately 6.43

Cyclacel Pharmaceuticals, Inc. Announces Quarterly Dividend For 6% Convertible Exchangeable Preferred Stock SHORT HILLS, NJ, APRIL 19, 2006 – Cyclacel Pharmaceuticals, Inc. ("Cyclacel", the "Company") (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that the Company's Board of Directors has declared

Cyclacel Pharmaceuticals To Present At BIO 2006 Annual International Convention SHORT HILLS, NJ, APRIL 6, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its pipeline at the